Enzo Biochem (ENZ) Hits New 12-Month Low at $3.48
Shares of Enzo Biochem, Inc. (NYSE:ENZ) reached a new 52-week low on Thursday . The company traded as low as $3.48 and last traded at $3.52, with a volume of 4725 shares traded. The stock had previously closed at $3.77.
ENZ has been the subject of a number of recent research reports. ValuEngine upgraded Enzo Biochem from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. TheStreet downgraded Enzo Biochem from a “c-” rating to a “d+” rating in a research report on Wednesday.
Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Tuesday, October 16th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.06). Enzo Biochem had a negative net margin of 9.86% and a negative return on equity of 13.25%. The company had revenue of $24.46 million during the quarter.
About Enzo Biochem (NYSE:ENZ)
Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.
Recommended Story: Diversification For Individual Investors
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.